Berry Street Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Berry Street Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-37,500	Closed	-$622K	–	32
2023 Q1	$622K	Buy	+37,500	New	+$437K	0.16%	26

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Berry Street Capital Management's BBIO Position: Q2 2023 in Review

Berry Street Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2023, closing a stake of 37,500 shares — an estimated $622K sold.

Berry Street Capital Management first reported a position in BBIO in Q1 2023 and held it in 1 quarter. The position peaked at $622K in Q1 2023. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

Berry Street Capital Management reported no remaining BridgeBio Pharma position as of Q2 2023 after selling out during the quarter.
Berry Street Capital Management sold 37,500 BridgeBio Pharma shares in Q2 2023, an estimated $622K.
Berry Street Capital Management first reported a position in BridgeBio Pharma in Q1 2023 and held it in 1 quarter.
Berry Street Capital Management's BridgeBio Pharma position peaked at $622K in Q1 2023.
197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on Berry Street Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.